NCT06989450 Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer
| NCT ID | NCT06989450 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sidekick Health |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-05-31 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2025-05-31 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized, controlled study to assess the effect of Sidekick Health's digital program on self-efficacy and medication adherence in breast cancer patients prescribed adjuvant anti-hormonal treatment. Participants will be treated with the digital program in addition to standard of care (SoC), or SoC only.
Eligibility Criteria
Inclusion Criteria: * Adult patient (18 years or older) diagnosed with breast cancer of stage I, II or III from 1st September 2023 or later * Have been prescribed adjuvant endocrine therapy for breast cancer. * Understands written and spoken Icelandic or English. * Owns a smart-phone compatible with the Sidekick app and capable to use it * Willing to download the Sidekick app on the smart-phone and to comply with the study measures and visits according to the protocol. * Capable of providing informed consent for participating in the study. Exclusion Criteria: * Having other concurrent conditions that in the opinion of the oncologist may compromise patient safety or study objectives. * Concurrent participation in another clinical study in which the study treatment may confound the evaluation of the investigational program. * Metastatic breast cancer (stage IV) * Previous experience with Sidekick breast cancer program
Contact & Investigator
Olof Kristjana Bjarnadottir, MD, PhD
PRINCIPAL INVESTIGATOR
Landspitali University Hospital
Frequently Asked Questions
Who can join the NCT06989450 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06989450 currently recruiting?
Yes, NCT06989450 is actively recruiting participants. Contact the research team at siggalara@sidekickhealth.com for enrollment information.
Where is the NCT06989450 trial being conducted?
This trial is being conducted at Reykjavik, Iceland.
Who is sponsoring the NCT06989450 clinical trial?
NCT06989450 is sponsored by Sidekick Health. The principal investigator is Olof Kristjana Bjarnadottir, MD, PhD at Landspitali University Hospital. The trial plans to enroll 140 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.